CellRev specializes in process intensification for cell manufacturing through advanced bioprocessing techniques that enhance yield and efficiency. The company reduces high production costs and lengthy timelines in biomanufacturing, facilitating faster and more cost-effective development of cell-based therapies.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell-based therapy and vaccine manufacturing faces challenges related to high production costs and extended timelines, hindering the efficient development and scalability of these therapies. Traditional cell culture methods often result in aggregation, clumping, and detachment issues, leading to reduced cell yield and increased process variability.
Solution
CellRev offers process intensification solutions for cell manufacturing, addressing bottlenecks in adherent cell culture workflows to enhance efficiency and reduce costs. Their proprietary media additives, including AggreGuard, are designed to mitigate cell-to-cell aggregation in microcarrier-based cell cultures by cleaving extracellular matrix components without harming the cells. By improving culture homogeneity and boosting cell viability, CellRev's solutions enable faster and more cost-effective development of cell-based products. These solutions are compatible with various commercially available microcarriers and adherent cell lines, facilitating seamless translation from research to commercial-scale manufacturing. CellRev also provides tailored process development services, leveraging their expertise to optimize upstream processes and future-proof customer workflows.
Target Audience
CellRev's primary customers are cell-based vaccine, therapy, and drug developers seeking to enhance the efficiency and scalability of their manufacturing processes.
Features
- AggreGuard media additive reduces cell-to-cell aggregation in microcarrier-based cell cultures.
- Proprietary enzymes gently digest extracellular matrix components to prevent cell adhesion.
- Enhances cell culture homogeneity, boosts cell viability, and increases process yield.
- Compatible with all commercially available microcarriers and adherent cell lines.
- Available in both Research and GMP grades.
- Tailored process development services to optimize upstream cell culture workflows.
- Proprietary processes combined with high-quality third-party equipment for innovative processing platforms.